1. Home
  2. EVI vs CBIO Comparison

EVI vs CBIO Comparison

Compare EVI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVI
  • CBIO
  • Stock Information
  • Founded
  • EVI 1959
  • CBIO 2003
  • Country
  • EVI United States
  • CBIO United States
  • Employees
  • EVI N/A
  • CBIO N/A
  • Industry
  • EVI Other Consumer Services
  • CBIO
  • Sector
  • EVI Consumer Discretionary
  • CBIO
  • Exchange
  • EVI Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • EVI 265.3M
  • CBIO 308.0M
  • IPO Year
  • EVI N/A
  • CBIO N/A
  • Fundamental
  • Price
  • EVI $24.75
  • CBIO $11.82
  • Analyst Decision
  • EVI Strong Buy
  • CBIO Strong Buy
  • Analyst Count
  • EVI 1
  • CBIO 3
  • Target Price
  • EVI $28.00
  • CBIO $25.67
  • AVG Volume (30 Days)
  • EVI 27.0K
  • CBIO 108.7K
  • Earning Date
  • EVI 09-11-2025
  • CBIO 08-23-2025
  • Dividend Yield
  • EVI 1.26%
  • CBIO N/A
  • EPS Growth
  • EVI 29.85
  • CBIO N/A
  • EPS
  • EVI 0.48
  • CBIO N/A
  • Revenue
  • EVI $370,020,000.00
  • CBIO N/A
  • Revenue This Year
  • EVI $25.04
  • CBIO N/A
  • Revenue Next Year
  • EVI N/A
  • CBIO N/A
  • P/E Ratio
  • EVI $51.34
  • CBIO N/A
  • Revenue Growth
  • EVI 3.51
  • CBIO N/A
  • 52 Week Low
  • EVI $14.51
  • CBIO $11.06
  • 52 Week High
  • EVI $27.69
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • EVI 64.94
  • CBIO N/A
  • Support Level
  • EVI $24.25
  • CBIO N/A
  • Resistance Level
  • EVI $27.69
  • CBIO N/A
  • Average True Range (ATR)
  • EVI 1.53
  • CBIO 0.00
  • MACD
  • EVI 0.21
  • CBIO 0.00
  • Stochastic Oscillator
  • EVI 68.81
  • CBIO 0.00

About EVI EVI Industries Inc.

EVI Industries Inc through its subsidiaries, is a distributor that sells, leases, and rents commercial, industrial, and vended laundry and dry cleaning equipment and steam and hot water boilers manufactured by others, supplies related replacement parts and accessories, designs and plans turn-key laundry, dry cleaning, and boiler systems, and provides installation and maintenance services to its customers, which include commercial, industrial, institutional, government, and retail customers. These activities are conducted in the United States, Canada, the Caribbean, and Latin America.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: